Overview

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

Status:
Recruiting
Trial end date:
2022-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HSY244 in participants with atrial fibrillation (AF), with and without heart failure (HF).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals